Next Article in Journal
Natural Killer Cell Activation Receptor NKp30 Oligomerization Depends on Its N-Glycosylation
Previous Article in Journal
Immune Suppressive Effects of Plasma-Derived Exosome Populations in Head and Neck Cancer
Open AccessReview

Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?

General Internal Medicine 4, Kawasaki Medical School, Okayama 700-8505, Japan
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1995; https://doi.org/10.3390/cancers12071995
Received: 24 June 2020 / Revised: 15 July 2020 / Accepted: 17 July 2020 / Published: 21 July 2020
Lung cancer patients ≥75 years represent nearly 40% of all lung cancer patients and continue to increase. If elderly patients have a good performance status and adequate organ function, they can be treated the same as non-elderly patients. However, few comparative studies limited to elderly patients (≥75 years) have been conducted. We review the evidence on using immune check inhibitors for the treatment of elderly patients (≥75 years old) with advanced non-small cell lung cancer. Prospective randomized or non-randomized, retrospective, registrational, insurance-based, and community-based studies have shown that elderly (≥75 years) and non-elderly patients are similarly treated with immune check inhibitors effectively and safely. However, such analyses have not shown that immune check inhibitors are significantly more effective than chemotherapy alone. In addition, patient selection might be critically performed to administer immune check inhibitors in the elderly because they are more likely to have a poor performance status with comorbidities, which lead to little benefit, even in non-elderly patients. There is a need for more evidence showing the benefit of immune check inhibitors in non-small cell lung cancer patients ≥75 years. View Full-Text
Keywords: elderly; immune checkpoint inhibitor; lung cancer elderly; immune checkpoint inhibitor; lung cancer
Show Figures

Figure 1

MDPI and ACS Style

Takigawa, N.; Ochi, N.; Nakagawa, N.; Nagasaki, Y.; Taoka, M.; Ichiyama, N.; Mimura, A.; Nakanishi, H.; Kohara, H.; Yamane, H. Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors? Cancers 2020, 12, 1995. https://doi.org/10.3390/cancers12071995

AMA Style

Takigawa N, Ochi N, Nakagawa N, Nagasaki Y, Taoka M, Ichiyama N, Mimura A, Nakanishi H, Kohara H, Yamane H. Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors? Cancers. 2020; 12(7):1995. https://doi.org/10.3390/cancers12071995

Chicago/Turabian Style

Takigawa, Nagio; Ochi, Nobuaki; Nakagawa, Nozomu; Nagasaki, Yasunari; Taoka, Masataka; Ichiyama, Naruhiko; Mimura, Ayaka; Nakanishi, Hidekazu; Kohara, Hiroyuki; Yamane, Hiromichi. 2020. "Do Elderly Lung Cancer Patients Aged ≥75 Years Benefit from Immune Checkpoint Inhibitors?" Cancers 12, no. 7: 1995. https://doi.org/10.3390/cancers12071995

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop